Abacavir (Ziagen) Research
2006-2012
- FDA-Led Research Team Discovers an Autoimmune Mechanism for Serious Drug-Induced Adverse Reactions (May 22, 2012)
From U.S. Food and Drug Administration
On TheBodyPRO.com
- FDA Study Finds No Link Between Ziagen and Heart Attacks (March 2011)
To read PDF, click here.
In HIV Treatment ALERTS!, from The Center for AIDS
On TheBodyPRO.com
- The Lingering Debate With Abacavir and Heart Disease (February 2010)
To read PDF, click here.
From Project Inform
- Tenofovir/Emtricitabine Performs Better Than Abacavir/Lamivudine in Subgroup of Antiretroviral-Naive, HIV-Infected Individuals (December 1, 2009)
From National Institute of Allergy and Infectious Diseases
On TheBodyPRO.com
- French Study Unexpectedly Uncovers Role of Substance Use in Heart Attacks (November 2009)
In Treatment Update, from Canadian AIDS Treatment Information Exchange
On TheBodyPRO.com
- Serious Non-AIDS Health Problems (Especially Heart Problems) Appear Less Likely With Truvada Than Epzicom, But Low Bone Mineral Density Is More Likely, Switch Study Finds (October 20, 2009)
In Clinical Infectious Diseases
- Abacavir Efficacy and Cardiovascular Risk (Winter/Spring 2009)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- DHHS Adults and Adolescents Antiretroviral Treatment Guidelines Panel's Communication Regarding Abacavir (April 4, 2008)
To read PDF, click here.
From AIDSinfo
- Major Study Finds Red Flags When Using Epzicom as First-Line Therapy in People With High Viral Load (February 28, 2008)
Combination therapy that includes ABC/3TC found less effective in subgroup of antiretroviral-naive individuals.
From U.S. National Institute of Allergy and Infectious Diseases
On TheBodyPRO.com
- Abacavir, Didanosine Associated With Higher Heart Attack Risk, D:A:D Study Finds (February 5, 2008)
An interview with Jens Lundgren, M.D.
In 15th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
VIEW ALL ARTICLES
2005
- Drugs to Reverse Lipoatrophy Show So-So Effects (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
- Low Incidence of Abacavir Hypersensitivity Reaction in Treatment-Naive and -Experienced Patients (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
On TheBodyPRO.com
- Adverse Event Risk on Abacavir + Lamivudine Is Not Higher for Patients Coinfected With Hepatitis B and/or Hepatitis C (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
On TheBodyPRO.com
- Once-Daily Abacavir + Lamivudine + Tenofovir Fails in Naive Patients (April 2005)
In Expert Opinion on Investigational Drugs, from TheBodyPRO.com
- Fixed-Dose Pill of Abacavir/Lamivudine Taken Once a Day Is Comparable to Twice-a-Day Abacavir + Lamivudine (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Sequencing and 2 of the Most Popular Backbone Regimens (February 25, 2005)
A comparison of resistance mutations with abacavir + lamivudine versus tenofovir + lamivudine.
In The 12th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Abacavir Is Not Associated With the Metabolic Changes Seen in Patients Treated With Stavudine (February 24, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Severity and Rate of Abacavir Hypersensitivity Reactions Higher Than Previously Believed (February 23, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
2004
- Tenofovir and Abacavir Do Not Interact in Patients on Triple-Nucleoside Regimens (July 13, 2004)
In The XV International AIDS Conference, from TheBodyPRO.com
- Failure of Tenofovir/Abacavir/Lamivudine Combination Still Unexplained (July 13, 2004)
In The XV International AIDS Conference, from TheBodyPRO.com
- Lamivudine/Abacavir Is an Effective Nucleoside Backbone in Combinations Other Than With Tenofovir (July 13, 2004)
Results suggest that the K65R mutation is behind the failure of this three-drug combination.
In The XV International AIDS Conference, from TheBodyPRO.com
- Abacavir Hypersensitivity Reaction Predicted by Genetic Test (March 26, 2004)
Research in Australia suggests the experimental test could drastically reduce hypersensitivity reactions, but is prone to false positives.
In AIDS Treatment News, from AIDS Treatment News
On TheBodyPRO.com
- Virologic Failure Analyzed in a Trial of Once-Daily Versus Twice-Daily Abacavir/3TC Regimens (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Improvement in Lipoatrophy Associated With Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Patients Switched from Stavudine to Abacavir or Zidovudine: The Results of the TARHEEL Study (January 15, 2004)
When people who had developed lipoatrohpy while taking d4T (stavudine, Zerit) switched to abacavir (Ziagen) or AZT (zidovudine, Retrovir), their condition improved.
In Clinical Infectious Diseases
- Update on the Safety and Efficacy of Abacavir (July 14, 2004)
In The XV International AIDS Conference, from TheBodyPRO.com
2003
- Reasons for Early Abacavir Discontinuation in HIV-Infected Patients (November 2003)
Abstract of a study in the Annals of Pharmacotherapy.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Clinical Risk Factors for Hypersensitivity Reactions to Abacavir: Side Effects of Antiretroviral Therapy (September 17, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
- Interim Analysis of Failure of Tenofovir/Abacavir/3TC Regimen (September 16, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
- Can Abacavir Be Given Once-a-Day? (September 16, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
- Emergence of Resistance-Associated Mutations Over 96 Weeks in Patients Initiating ABC/3TC + d4T, EFV or APV/r (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
- Abacavir Not Inferior to AZT in Treatment-Naive Patients (September 14, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
- Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients With Human Immunodeficiency Virus Infection (September 11, 2003)
In The New England Journal of Medicine
- Viread, Epivir and Ziagen Combination -- Failure in Naive Patients With a Once-Daily Regimen (September/October 2003)
Daniel S. Berger, M.D., chief investigator in study ESS30009, examines what went wrong.
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
On TheBodyPRO.com
- Early Virologic Non-Response in Patients With HIV Infection Treated With Lamivudine, Abacavir and Tenofovir (July 25, 2003)
"Dear Healthcare Provider" letter from GlaxoSmithKline.
From U.S. Food and Drug Administration
On TheBodyPRO.com
- Combivir + Abacavir Better Tolerated and More Potent Than Combivir + Nelfinavir (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
VIEW ALL ARTICLES
2002
- Secondary Syphilis and Abacavir Hypersensitivity Reaction (October 26, 2002)
In 40th Annual Meeting of the Infectious Diseases Society of America, from TheBodyPRO.com
- Lack of Recurrence of Symptomatic and Asymptomatic Hyperlactatemia When Stavudine Is Replaced by Either Abacavir or Zidovudine: 48-Week Data (September 24, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from TheBodyPRO.com
- Genotypic and Virtual Phenotypic Correlates of Virologic Response to Abacavir-Based Therapy in the ZORRO Trial (ESS40009) (July 11, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
- Abacavir Substitution for Nucleoside Analogs in Patients With HIV Lipoatrophy (July 10, 2002)
In Journal of the American Medical Association
- Switching Protease Inhibitors to Nevirapine, Efavirenz or Abacavir: A Randomized, Multicenter, Open-Label, Simplification Trial (July 10, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
- Abacavir Use in HIV-Positive Pregnant Women (July 10, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
- Simplification of Protease Inhibitor-Based Highly Active Antiretroviral Regimens With Abacavir Improves Hyperlipidemia and Maintains Viral Suppression in HIV-1-Infected Adults (ESS40003) (July 10, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
- Phenotypic and Genotypic Profiles Predict Week 24 Responses to an Abacavir-Containing Salvage Regimen (July 9, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
- Durability and Tolerability of the Triple NRTI Regimen Abacavir/Zidovudine/Lamivudine Based on Therapy Changes in Antiretroviral Therapy-Naive Patients in the Frankfurt HIV Cohort (July 9, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
- Successful Intensification of Antiretroviral Therapy With Abacavir in Clinical Practice (July 9, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
VIEW ALL ARTICLES
1998-2001
- Diverse Effects of NRTI-Associated Mutations on Resistance to Abacavir, Stavudine and Zidovudine in the ZORRO Trial (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from TheBodyPRO.com
- Virologic Response to Abacavir/Efavirenz/ddI + Hydroxyurea in Subjects Failing Initial NRTI + PI Therapy (NZTA4008 Study) (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from TheBodyPRO.com
- Simplification of Protease Inhibitor-Containing HAART Regimen With Abacavir Maintains Viral Suppression and Favorable Adherence in HIV-1 Infected Adults (October 27, 2001)
In 39th Annual Meeting of the Infectious Diseases Society of America, from TheBodyPRO.com
- The Compact Quad, Combivir/Abacavir/Efavirenz -- Preliminary 48-Week Results (October 27, 2001)
In 39th Annual Meeting of the Infectious Diseases Society of America, from TheBodyPRO.com
- Prospective Study of Hyperlipidemia in ART-Naive Subjects Taking Abacavir/Combivir/Nelfinavir, or Lamivudine/Stavudine/NFV (GSK Protocol ESS40002) (October 26, 2001)
In 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from TheBodyPRO.com
- Risk Factor Analysis of Hypersensitivity Reactions to Abacavir: Retrospective Analysis of 25 Clinical Trials (July 10, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
- Short-Term Immuno-Suppressive Therapy With Prednisolone in HIV-1-Infected Patients Receiving Abacavir With or Without Nevirapine (July 10, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
- Abacavir/Combivir Is Comparable to Indinavir/Combivir in HIV-1 Infected Antiretroviral Therapy Naive Adults: Preliminary Results of a 48-Week Open-Label Study (CNA3014) (July 10, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
- A Randomized Open Label Study to Investigate Abacavir and Lamivudine as Once-Daily Components of a Triple-Combination Regimen (July 9, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
- Comparison of Symptoms of Influenza A Infection With Abacavir-Associated Hypersensitivity Reaction (February 7, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
VIEW ALL ARTICLES
Older
|
|
Advertisement
|
Email
Glossary
